Skip to main content Accessibility help
×
Home

The Argatroban and tPA Stroke Study

  • Andrew D. Barreto (a1) and James C. Grotta (a2)

Extract

ABSTRACT

Background: The benefit of intravenous recombinant tissue plasminogen activator (rtPA) in acute ischemic stroke is related to clot lysis and arterial recanalization. Argatroban is a direct thrombin inhibitor that safely augments the benefit of rtPA in animal stroke models. However, human data on this combination are limited. Design: We report an update of the Argatroban tPA Stroke Study, an ongoing prospective, open-label, dose escalation, safety, and activity study of argatroban and rtPA in patients with ischemic stroke. The primary outcome was incidence of intracerebral hemorrhage; secondary outcome, complete recanalization at 2 h. After standard dose intravenous rtPA administration, a 100-μg/kg bolus of argatroban followed by infusion of 1 μg/kg per min for 48 h was adjusted to a target partial thromboplastin time of 1.75 times baseline. Results: Twenty patients with middle cerebral artery occlusions (including 13 men) have been enrolled, with a mean ± SD age of 61 ± 13 years. Baseline median National Institute of Health Stroke Scale score was 12.5 (range, 3–25). The mean ± SD time from symptom onset to argatroban bolus administration was 177 ± 56 min. Symptomatic intracerebral hemorrhage occurred in 2 patients, including 1 with parenchymal hemorrhage type 2. Asymptomatic bleeding occurred in 2 patients and there was 1 death. Recanalization was complete in 7 patients and partial in another 7, and reocclusion occurred in 4 within 2 h of rtPA bolus administration. Conclusion: The combination of low-dose argatroban and intravenous rtPA may be safe, and produce faster and more complete recanalization, but a larger cohort of patients is required to confirm this pilot study.

Copyright

Corresponding author

Correspondence should be addressed to: Andrew D. Barreto, MD, Department of Neurology, Stroke Division, The University of Houston-Texas, 6431 Fannin – MSB 7.128, Houston, TX 77030, USA; Ph: +1 713 500 7002; Fax: +1 713 500 0660; Email: andrew.d.barreto@uth.tmc.edu

References

Hide All

References

Alexandrov, A.V., & Grotta, J.C. (2002). Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology, 59, 862867.
Alexandrov, A.V., Burgin, W.S., Demchuk, A.M., El-Mitwalli, A., & Grotta, J.C. (2001). Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation, 103, 28972902.
Alexandrov, A.V., Demchuk, A.M., Burgin, W.S., Robinson, D.J., & Grotta, J.C. (2004a). Ultrasound-enhanced thrombolysis for acute ischemic stroke, phase I: findings of the CLOTBUST trial. Journal of Neuroimaging, 14, 113117.
Alexandrov, A.V., Molina, C.A., Grotta, J.C., et al. (2004b). Ultrasound enhanced systemic thrombolysis for acute ischemic stroke. New England Journal of Medicine, 351, 21702178.
Alexandrov, A.V., Wojner, A.W., & Grotta, J.C. (2004c). CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. Journal of Neuroimaging, 14, 108112.
Arg-231 Clinical Study Report (1999). A Randomized, Single-Blind Study of Two Doses of Novastan Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator in Acute Myocardial Infarction: MINT Study. Houston, TX: Texas Biotechnology Corporation.
Ciccone, A., Abraha, I., & Santilli, I. (2007). Glycoprotein IIb-IIIa inhibitors for acute ischemic stroke. Stroke, 38, 11131114.
Demchuk, A.M., Burgin, W.S., Christou, I., et al. (2001). Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke, 32, 8993.
Fiorelli, M., Bastianello, S., von Kummer, R., et al. (1999). Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke, 30, 22802284.
Hacke, W., Kaste, M., Fieschi, C., et al. (1998). Second European-Australian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet, 352, 12451251.
Hacke, W., Brott, T., Caplan, L., et al. (1999). Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology, 53, S3S14.
Investigator's Brochure for Argatroban (2001). Houston, TX: Texas Biotechnology Corporation.
Jang, I.K., Gold, H.K., Leinbach, R.C., Fallon, J.T., & Collen, D. (1990). In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circulation Research, 67, 15521561.
Jang, I.K., Brown, D.F., Giugliano, R.P., et al. (1999). A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (Tpa) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) study. Journal of the American College of Cardiology, 33, 18791885.
Kawai, H., Umemura, K., & Nakashima, M. (1995). Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Japanese Journal of Pharmacology, 69, 143148.
Kobayashi, S., & Tazaki, Y. (1997). Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Seminars in Thrombosis and Hemostasis, 23, 531534.
Labiche, L.A., Al-Senani, F., Wojner, A.W., Grotta, J.C., Malkoff, M.A., & Alexandrov, V. (2003). Is the benefit of early recanalization sustained at 3 months? a prospective cohort study. Stroke, 34, 695698.
LaMonte, M.P., Nash, M.L., Wang, D.Z., et al. (2004). Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke, 35, 16771682.
Moledina, M., Chakir, M., & Gandhi, J.P. (2001). A synopsis of the clinical uses of argatroban. Journal of Thrombsis and Thrombolysis, 12, 141149.
Morris, D.C., Zhang, L., Zhang, Z.G., et al. (2001). Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke, 32, 26352640.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine, 333, 15811587.
Sugg, R.M., Pary, J.K., Uchino, K., et al. (2006). Argatroban tPA stroke study: study design and results in the first treated cohort. Archievs of Neurology, 63, 10571062.
Tamao, Y., & Kikumoto, R. (1997). Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis. Seminars in Thrombosis and Hemostasis, 23, 523530.
Tanaka, K.A., Szlam, F., Katori, N., Sato, N., Vega, J.D., & Levy, J.H. (2004). The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesthesia and Analgesia, 99, 12831289.
Tanaka, Y., Kawabata, S., Sin, R., et al. (1987). Therapeutic effect of argatroban (MD-805), antithrombotic agent, in the acute stage of cerebral thrombosis. Journal of Clinical and Therapeutic Medicine, 3, 133142.
The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators (1998). Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA, 279, 12651272.
Walenga, J.M. (2002). An overview of the direct thrombin inhibitor argatroban. Pathophysiology of Haemostasis and Thrombosis, 32 (suppl. 3), 914.
www.clinicaltrials.gov Identifier: NCT00268762. Accessed September 28, 2007.
Wykrzykowska, J.J., Kathiresan, S., & Jang, I.K. (2003). Clinician update: direct thrombin inhibitors in acute coronary syndromes. Journal of Thrombsis and Thrombolysis, 15, 4757.

Keywords

Related content

Powered by UNSILO

The Argatroban and tPA Stroke Study

  • Andrew D. Barreto (a1) and James C. Grotta (a2)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.